<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459328</url>
  </required_header>
  <id_info>
    <org_study_id>E33034</org_study_id>
    <nct_id>NCT01459328</nct_id>
  </id_info>
  <brief_title>Resource-Sparing Curative Treatment for Rectal Cancer</brief_title>
  <official_title>Resource-Sparing Curative Treatment for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Anti Cancer Hopital Frantz Fanon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital A.C. Camargo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Credit Valley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Cancerologia, Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital &quot;Sestre Milosrdnice&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minesterio de Cienca, Tecnologia y Medio Ambiente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>V.N. Cancer Center GKNM Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Bratislava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Atomic Energy Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentre, randomized clinical trial comparing two different
      neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced
      adenocarcinoma of the rectum.

      This trial may establish the investigational therapy to be superior to, or at least not
      inferior to conventional treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III randomised clinical trial compares the outcome of two different neo-adjuvant
      radiation based treatments for locally advanced rectal carcinoma. This encompasses patients
      at risk for a positive circumfrential resection margin (CRM+) on baseline assessment imaging
      and pateints identified as being with a T-descriptor T4 at baseline assessment.

      The arms compared are as follows:

        -  The investigational arm: short chemo-radiation course(25Gy in 5 daily fractions over 1
           week) +/- surgery.

        -  The conventional arm: protracted chemo-radiation course (50Gy in 25 daily fractions over
           5 weeks combined with chemotherapy)+/- surgery.

      The outcomes include four domains: overall survival, biological effect, quality of life and
      health-related economics.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From commencement of radiation (day 1) to death or last follow-up up to 5 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological Effect and Tumour Biology</measure>
    <time_frame>Prior to surgical decision in weeks 13-15 and 4 weeks after surgery</time_frame>
    <description>Maximum size of the tumor based on imaging and/or up to 3D measures reported by radiologists, comparing baseline and pre-surgical decision inverstigations
If definitive surgery is conducted:
Proportion obtaining R0
Proportion undergoing TME
Status of the neurovascular and neural invasion(s)
Nodal ratio
Tumor sizes
CEA results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From date of randomization till the end of follow-up (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Economics</measure>
    <time_frame>From date of randomization till the end of follow-up (5 years)</time_frame>
    <description>Number of days in hospital
Number of surgical procedures
Number of days with stomas
Protocol required therapies, as actually administered
Adverse events that have significant cost implications (i.e. cost-drivers)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Rectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Conventional Long Course Chemo-Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional long course chemo-radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Short Course Radiation Followed by Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental short course radiation followed by chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day
Injected Leucovorin 20 mg/m2/day for 5 days</description>
    <arm_group_label>Arm B: Short Course Radiation Followed by Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Conventional long course chemo-radiation:
Radiation 50Gy in 25 daily fractions over 5 weeks
Bolus 5 Fluorouracil 350mg/m2/d for 5 days
Injected Leucovorin 20mg in both the first and last (5th) week of radiation
Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks.</description>
    <arm_group_label>Arm A: Conventional Long Course Chemo-Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Clinical (i.e. surgical determination) and/or diagnostic image findings consistent
             with c/uT4 or CRM+ (note that CRM+ must be established by MRI), primary rectal
             Adenocarcinoma (i.e. histology consistent with origin from rectal mucosa); these
             constitute LARC for the purpose of this protocol

          -  Treatment will be directed at the primary cancer, being clinically appropriate and
             given with an initial intent to cure the patient (this includes accepting up front
             that radiation and surgery are feasible; for surgery, this means that the patient has
             been determined fit for major surgery by an anaesthesiologist prior to the request for
             randomization)

          -  Performance status is sufficient to undertake the treatment in either arm (KPS&gt;50%)

          -  Patient is accessible for required follow-up and data collection

          -  Radiation oncologist expects survival to exceed 6 months from date of diagnosis

          -  Patient provides informed consent

        Exclusion Criteria:

          -  Recurrent rectal cancer

          -  Primary wholly in the sigmoid colon

          -  Considered to be arising in the anal canal

          -  Metastatic disease beyond the pelvis (by clinical assessment and/or diagnostic
             imaging)

          -  Contraindications to protocol RT or to protocol chemotherapy, such as one or more of
             the following:

          -  any prior RT to the pelvis; a solitary pelvic kidney within the intended radiation
             volume

          -  consideration by the most responsible radiation oncologist that the treatment volume
             is too large, or the amount of small bowel or other critical organs within the
             treatment volume is too much for safe treatment

          -  significantly abnormal laboratory tests such as impaired renal/liver function

          -  a haemoglobin that is &lt; 8.0 (or 80, SI) and the patient is not transfused to exceed
             8.0 (or 80, SI)

          -  on-going medications that are not compatible with protocol neo-adjuvant chemotherapy
             as described in this protocol

          -  Significant development issues (such as with age &lt; 18 yr)

          -  Co-morbidity

          -  Psychiatric diagnosis

          -  Physical impairment

          -  Pregnancy or continuing breast-feeding, that precludes administration of protocol
             treatments, or that precludes data collection (such as likely to preclude follow-up
             visits or completing questionnaires)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Rosenblatt</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Atomic Energy Agency</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IAEA</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Anti-Cancer, Hopital Franz Fanon</name>
      <address>
        <city>Blida</city>
        <zip>09000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boualga Kada</last_name>
      <phone>+213 25 415985</phone>
      <email>kboualga2002@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Boualga Kada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital A.C. Camargo, Fundacao Antonio Prudente</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Leticia Gobo Silva</last_name>
      <phone>+551132729613</phone>
      <email>mlgobo@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Maria Leticia Gobo Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jidong Lian</last_name>
      <email>ombudsman@cvh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Jidong Lian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia, Minesterio de Salud</name>
      <address>
        <city>Bogota D.C.</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalba Ospinp Pena</last_name>
      <phone>005713341997</phone>
      <email>rospino@cancer.gov.co</email>
    </contact>
    <investigator>
      <last_name>Rosalba Ospino Pena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology and Nuclear Medicine, University Hospital Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Frobe</last_name>
      <phone>+38513787468</phone>
      <email>afrobe@irb.hr</email>
    </contact>
    <investigator>
      <last_name>Blanka Jaksic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ministerio de Cienca, Tecnologia y Medio Ambiente (CITMA)</name>
      <address>
        <city>La Habana</city>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lourdes Pernez Pena</last_name>
      <phone>+5378316040</phone>
      <email>soconcol@infomed.sld.cu</email>
    </contact>
    <investigator>
      <last_name>Aixa Ulloa Balmaseda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, V.N. Cancer Center, GKNM Hospital</name>
      <address>
        <city>Coimbatore</city>
        <zip>Tamil Nadu 641 037</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagarajan Murugaiyan</last_name>
      <phone>+9104222216715</phone>
      <email>mnagarajan@gknmh.org</email>
    </contact>
    <contact_backup>
      <email>mnr81@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nagarajan Viswanathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>Maharashtra 400 012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Engineer</last_name>
      <phone>+912224177163</phone>
      <email>reena_engineer@rediffmail.com</email>
    </contact>
    <contact_backup>
      <phone>+912224177000</phone>
    </contact_backup>
    <investigator>
      <last_name>Shyam Kishore Shrivastava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Radiotherapy, Dr. Cipto Mangunkusuma National General Hospital, University of Indonesia</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sri Mutya Sekarutami</last_name>
      <phone>+62213921155</phone>
      <email>smutya12@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Sri Mutya Sekarutami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto di Radiologia, Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Valentini</last_name>
      <phone>+390630154376</phone>
      <email>vvalentini.it@email.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Valentini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margita Pobijakova</last_name>
      <phone>+421259378579</phone>
      <email>margita.pobijakova@nou.sk</email>
    </contact>
    <investigator>
      <last_name>Margita Pobijakova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7701</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Robertson</last_name>
      <email>Barbara.robertson@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Barbara Robertson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Cuba</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.</citation>
    <PMID>16971718</PMID>
  </reference>
  <reference>
    <citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001 Aug 30;345(9):638-46.</citation>
    <PMID>11547717</PMID>
  </reference>
  <reference>
    <citation>Radu C, Berglund A, Påhlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008 Jun;87(3):343-9. Epub 2008 Feb 21.</citation>
    <PMID>18093674</PMID>
  </reference>
  <reference>
    <citation>Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008 Aug 1;26(22):3687-94. doi: 10.1200/JCO.2007.15.3858.</citation>
    <PMID>18669453</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal carcinoma</keyword>
  <keyword>long course chemo-radiation</keyword>
  <keyword>short course chemo-rdiation</keyword>
  <keyword>Locally Advanced Rectal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

